Trade Summary

3 days ago, Robin Howard W, serving as Pres, CEO at Nektar Therapeutics (NKTR), sold 423 shares at $73.00 per share, for a total transaction value of $30,879.00. Following this transaction, Robin Howard W now holds 75,517 shares of NKTR.

This sale represents a 1.00% decrease in Robin Howard W's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 2 days after the trade was made.

Nektar Therapeutics operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.